Caprine herpes virus-1 reduces cell viability and enhances chemosensitivity in breast cancer cells
Carmelina Antonella Iannuzzi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Iris Maria Forte(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Roberto Ciarcia(Federico II University Hospital), Sara Damiano(Federico II University Hospital), Serena Montagnaro(University of Naples Federico II), Stefania Cocco(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alessandra Calabrese(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Claudia von Arx(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Matteo Tomeo(Scuola Superiore Meridionale), Antonio Giordano(Harvard University), Anna Sfera(University of Siena), Francesco Pagano(University of Salerno), R. Carmerlingo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Luigi Alfano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 0
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282